Jaeinrnp
Seoul, KR ยท 2 known investors
Seoul-based Jaein R&P develops natural-product anticancer drug candidates, led by clinical-stage botanical compound SH003.
Also known as (์ฃผ)์ฌ์ธ์์คํผ ยท Jaein R&P ยท Jaein R&P Corp ยท ์ฌ์ธ R&P ยท ์ฌ์ธ์์คํผ
Investors ยท 2
Also in the syndicate ยท 1
Company profile
researched Aug 2026Jaein R&P Corp ((์ฃผ)์ฌ์ธ์์คํผ) is a Seoul-based drug development company focused on natural-product (botanical) therapeutics for cancer treatment, prevention and management. The company states it was established in April 2017 and is headquartered at the Seoul Bio Hub Global Center, 117-3 Hoegi-ro, Dongdaemun-gu, Seoul, having relocated its head office in May 2021 after being selected as a tenant of the 2021 Seoul Bio industry-academia cooperation center.
Its disclosed pipeline consists of three programs: SH003, JI021 and JI017. SH003 is the lead asset: the company reports completing a Phase 1 trial in July 2019, receiving IND approval in November 2019 for a Phase 2 study in non-small cell lung cancer (NSCLC), and receiving IND approval in March 2020 for a high-dose (monotherapy) Phase 1 study. Domestic and international patents covering SH003 were obtained in November 2018, with a US international patent registration in January 2020; a separate program, Ato-Jin, was filed internationally (Europe, USA) in 2019. Alongside prescription drug development, the company plans a health functional food (nutraceutical) product derived from SH003 research, targeting registration as an individually approved functional ingredient as an early milestone, with subsequent licensing-out or in-house manufacturing and distribution left open. JI021 has shown inhibition of cancer cell proliferation in cell and animal experiments, which the company cites as the basis for exploring it as an additional pipeline candidate.
Founding story
Company materials state that Jaein R&P was established in April 2017 and describe its origin as a pursuit of better health and quality of life through drugs for the treatment, prevention and management of cancer.
Business model
Development of natural-product-based anticancer drug candidates, with intellectual property secured through domestic and international patents. For its planned health functional food derived from SH003 research, the company says it will decide flexibly between licensing out (L/O) and direct in-house manufacturing and distribution after regulatory approval.
The company describes a strategy of launching a health functional food based on results from SH003 research and development in order to generate revenue earlier than drug approval, while retaining its identity as a natural-product new drug developer; longer term options include out-licensing or self-manufactured product sales.
Traction
Clinical and IP milestones reported by the company include completion of a SH003 Phase 1 trial (July 2019), Phase 2 IND approval for SH003 in NSCLC (November 2019), a high-dose monotherapy Phase 1 IND approval (March 2020), Korean and international SH003 patents including a US registration (January 2020), and membership in Seoul Bio Hub and bio-health startup center programs. It also reported a KRW 1 billion investment from DT&Investment in February 2021 and additional fundraising activity later that year.
Latest developments
The most recent items published by the company are dated 2021: relocation of its head office in May 2021 after selection as a 2021 Seoul Bio industry-academia cooperation center tenant, a July 2021 note that three to four VC, strategic and angel investors were in process for approximately KRW 3 billion, and a November 2021 investment. The site's news section features press coverage of technology commercialization at Korea's 12 special research and development innovation zones.
โธFull profile โ market position, technology, go-to-market, geography, history
Market position
The company positions its planned anticancer health functional food against existing products and ingredients in Korea, citing HemoHIM, AHCC, Rockfeed and Abnobaviscum, and notes that mistletoe injections are used in tertiary hospital oncology routines as evidence of demand for adjunct supplements in cancer care. It benchmarks HemoHIM's commercialization model โ combining Korea Atomic Energy Research Institute R&D, Kolmar manufacturing and Atomy distribution โ and cites HemoHIM cumulative sales figures of KRW 9 billion in 2009, KRW 181.9 billion in 2018 and KRW 1,130.5 billion in 2019, within a Korean health functional food market it describes as roughly KRW 4 trillion annually.
The company argues few health functional foods have received comparable levels of capital investment in basic research and development to SH003, and that its products rest on patents developed over more than 15 years at Kyung Hee University's College of Korean Medicine.
Technology
Natural-product (botanical) pharmacology assets developed around SH003, JI021 and JI017. SH003 and related inventions are covered by Korean and international patents, including a US registration in 2020, and the company states the underlying patents come from more than 15 years of research and development at the College of Korean Medicine, Kyung Hee University. JI021 has demonstrated inhibition of cancer cell proliferation in in vitro and animal studies. A further program, Ato-Jin, was filed for international patent protection in Europe and the USA.
Go-to-market
Regulatory-milestone-driven: registration as an individually approved functional ingredient is set as an initial milestone for the nutraceutical program, after which the company may license out or manufacture and distribute directly. For therapeutics, the company says it intends to pursue open innovation with domestic and overseas ventures and universities to increase the speed and probability of success of new drug development.
Cancer patients requiring treatment, prevention and post-treatment management, addressed through prescription drug candidates and an anticancer-oriented health functional food; partners include pharmaceutical licensees and distribution partners.
Geography
Headquartered in Dongdaemun-gu, Seoul, South Korea (Seoul Bio Hub Global Center, room 304). Patent activity extends to the United States and Europe, and the company states it aims to conduct research and development for cancer treatment globally rather than domestically only.
History
Per the company's published timeline: founded April 2017; SH003-related domestic and international patents obtained November 2018; Ato-Jin international patent applications filed in Europe and the USA in 2019; membership in a bio-health innovation startup center in July 2019 and in the Seoul Bio Hub Innovation Startup Center in October 2019; SH003 Phase 1 completed July 2019; Phase 2 IND approval for SH003 in NSCLC in November 2019; SH003 international (USA) patent registration January 2020; IND approval for a high-dose single-agent SH003 Phase 1 in March 2020; investment from DT&Investment (KRW 1 billion) in February 2021; head office relocation in May 2021 upon selection as a tenant company of the 2021 Seoul Bio industry-academia cooperation center; in July 2021 the company reported discussions in progress with three to four VC, strategic and angel investors for approximately KRW 3 billion; and a further investment noted in November 2021.
Compiled by commissioned research from 8 cited public sources โ announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed โ not independently audited.
Timeline ยท 13
launches, deals, and filingsCompany timeline states investment processes were underway with three to four VC, SI and angel investors for approximately KRW 3 billion.
Company history page records an investment of KRW 1 billion (10์ต์) from DT&Investment (๋ํฐ์ค ์ธ๋ฒ ์คํธ๋จผํธ).
Company timeline lists the Ato-Jin international patent filing under 2019 (shown as March in one listing and April in another).
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
โธResearch sources ยท 8
primary sources listed
- Jaeinrnpjaeinrnp.com ยท web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Jaeinrnp do?
- Seoul-based Jaein R&P develops natural-product anticancer drug candidates, led by clinical-stage botanical compound SH003.
- Who are Jaeinrnp's investors?
- Jaeinrnp's investors include Colopl Next.
- Where is Jaeinrnp headquartered?
- Jaeinrnp is headquartered in Seoul, KR.